On June 2, 2025, Sandoz announced the launch of its Wyost/Jubbonti denosumab biosimilar, the first of this drug category to be marketed. In a press release, Keren Haruvi, President, Sandoz North America, stated, “Denosumab is a vital medicine for conditions such as osteoporosis and cancer-related skeletal events. Providing an additional high-quality, cost-effective treatment option helps … Continue reading The First Denosumab Biosimilar Reaches the US Market